BioOva Oocyte extract Caner Treatment: Cancer, also called malignancy, is an abnormal growth of cells. There are more than 100 types of cancer, including breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. Symptoms vary depending on the type. Cancer treatment may include chemotherapy, radiation, and/or surgery.
According to estimates from the International Agency for Research on Cancer (IARC), in 2012 there were 14.1 million new cancer cases and 8.2 million cancer deaths worldwide. By 2030, the global burden is expected to grow to 21.7 million new cancer cases and 13 million cancer deaths simply due to the growth and aging of the population. The future burden will probably be even larger because of the adoption of western lifestyles, such as smoking, poor diet, physical inactivity, and fewer childbirths, in economically developing countries.
Cancer cells come from healthy cells, the understanding every cell comes from a cell is globally accepted. Sometimes mutations or errors in the coding of the cell can occur. This can be due to environmental factors, genetic factors and ill health. In vitro BioOva oocyte extract has a remarkable ability to reprogram cells, altering the mutation to its original health cell structure. Many patients have had complete remission occur after using BioOva to treat Cancer.
Cancer Treatment - Reprogram Cancer Cells
Breast Cancer Treatment Results
Breast Cancer Treatment - Reprogram Cancer Cells with BioOva Oocyet extract: Clinical study results obtained from female metastatic breast cancer patient, who received IM BioOva treatment for the period of 8 months listed in figures 12-14. Down regulation of all three major tumor markers such as cancer-associated antigen (CA 27.29), carcinoembryonic antigen (CEA) and hydrolysis enzyme Alkaline Phosphatase (ALP) indicates that BioOva extract formulation can be effective in the treatment of this prevalent oncologic disease. For example, by the end of BioOva oocyte extract therapy, blood antigen detection test revealed considerable down regulation of one of the most important tumor cancer-associated antigen (CA 27.29). For example, from September 23, 2013 when BioOva treatment commenced until its completion on March 10, 2014 CA27-29 levels decreased from 3222.8 U/ml to 1691.0 U/ml which represents 47% drop (Fig.12)
Analogical tendency observed for carcinoembryonic antigen (CEA) levels which for the same period of BioOva treatment down regulated from 40.1µg/L to 10.8 µg/L or 33% drop (Fig. 13)
Activity of hydrolysis enzyme alkaline phosphatase (ALP) in blood samples of MBC patient also substantially down regulated since initiation of treatment (Fig/14). For the whole period of observation, between September 23,2013 and March 10, 2014 APL activity dropped from 297 U/L to 135 U/L which represents 54.5% decrease. During the period of BioOva treatment MBC patient gained body weight and showed considerable improvement in all vital signs. Patient still alive though presently is taken off Bioova treatment.